LOS ANGELES–(BUSINESS WIRE)–ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world’s most respected quality management standard. This accreditation covers testing of the Company’s Tru Niagen® consumer products, its Niagen® ingredient, and phytochemical reference standards performed out of its quality control and R&D facility in Longmont, Colorado. The accreditation requires demonstration of full and continuous compliance with the most rigorous ISO quality standards, enabling ChromaDex to test and analyze its Tru Niagen® product, ingredients, and reference standards.
The ISO 17025 accreditation validates the technical proficiency of the state-of-the-art ChromaDex laboratory and its proven ability to consistently generate highly accurate, scientifically defensible product quality data that is traceable to and compliant with international standards.
“This latest accreditation recognizes ChromaDex’s consistency in meeting the highest international standards in quality control,” ChromaDex CEO Rob Fried commented. “Our global partners such as Nestlé have learned to expect these designations along with world-class clinical data.”
Dr. Andrew Shao, ChromaDex Senior Vice President of Global Scientific & Regulatory Affairs, added, “The quality and reliability of our products is affirmed through this process. This accreditation helps provide health regulators with confidence in the quality and science behind our products in markets across the globe.”
Niagen® is tested under ChromaDex’s ISO/IEC 17025:2017 accreditation and is the only commercially available nicotinamide riboside (NR) which has twice been successfully reviewed under U.S. Food & Drug Association’s (FDA) new dietary ingredient (NDI) notification requirement and successfully notified to the FDA as generally recognized as safe (GRAS). ChromaDex has also secured regulatory approval on its patent-protected Niagen® ingredient in Canada, Australia, and the European Union.
For additional information on ChromaDex, visit www.chromadex.com.
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of NAD and its impact on human health. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects”, “anticipates”, “intends”, “estimates”, “plans”, “potential”, “possible”, “probable”, “believes”, “seeks”, “may”, “will”, “should”, “could” or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.